Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
K A KirnichnayaE M Krupitsky

Abstract

"Typical" antipsychotics remain the wide-prescribed drugs in modern psychiatry. But these drugs are associated with development of extrapyramidal symptoms (EPS). Preventive methods of EPS are actively developed and they concentrate on personalized approach. The method of taking into account genetic characteristics of patient for prescribing of treatment was proven as effective in cardiology, oncology, HIV-medicine. In this review the modern state of pharmacogenetic research of antipsychotic-induced EPS are considered. There are pharmacokinetic and pharmacodynamic factors which impact on adverse effects. Pharmacokinetic factors are the most well-studied to date, these include genetic polymorphisms of genes of cytochrome P450. However, evidence base while does not allow to do the significant prognosis of development of EPS based on genetic testing of CYP2D6 and CYP7A2 polymorphisms. Genes of pharmacodynamics factors, which realize the EPS during antipsychotic treatment, are the wide field for research. In separate part of review research of such systems as dopaminergic, serotonergic, adrenergic, glutamatergic, GABAergic, BDNF were analyzed. The role of oxidative stress factors in the pathogenesis of antipsychotic-induced EPS was ...Continue Reading

References

Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·T NishikawaY Uchida
Aug 1, 1983·The British Journal of Psychiatry : the Journal of Mental Science·W M BraudeS M Gore
Jun 1, 1995·Journal of Clinical Psychopharmacology·H ArthurF Sjöqvist
Jan 1, 1996·Annual Review of Neuroscience·G R Lewin, Y A Barde
Jan 1, 1997·Nutrition Reviews·B Halliwell
Jun 17, 1998·Biological Psychiatry·L A AdlerJ Rotrosen
Sep 5, 1998·Journal of Inherited Metabolic Disease·B H Robinson
Jul 7, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H HoriJ Nakamura
Jul 8, 2000·Proceedings of the National Academy of Sciences of the United States of America·P Seeman, S Kapur
Jan 12, 2001·European Archives of Psychiatry and Clinical Neuroscience·A Jablensky
May 1, 2001·The American Journal of Psychiatry·F M TheisenJ Hebebrand
Nov 28, 2001·Acta Psychiatrica Scandinavica·D J MüllerM Rietschel
Mar 22, 2002·Clinical Pharmacology and Therapeutics·Elena García-MartínJosé A G Agúndez
Jun 8, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·Pierre-Michel LlorcaChristophe Lancon
Jun 14, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bernard LererFabio Macciardi
Dec 7, 2002·CNS Drugs·James B LohrAlexander B Niculescu
Dec 24, 2002·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Siow-Ann ChongYiong Huak Chan
Apr 2, 2003·Drugs of Today·Shrinivas K Kulkarni, Pattipati S Naidu
May 8, 2003·Pharmacopsychiatry·P L LohmannM L Rao
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Mar 16, 2004·CNS Drugs·Jeffrey A Lieberman
Sep 24, 2004·The International Journal of Neuropsychopharmacology·Enrico LattuadaEnrico Smeraldi
Oct 12, 2004·Schizophrenia Research·Karmen K YoderAnantha Shekhar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here